Compounds > moxifloxacin
Page last updated: 2024-09-04

moxifloxacin and Hematologic Neoplasms

moxifloxacin has been researched along with Hematologic Neoplasms in 4 studies

Research

Studies (4)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (25.00)29.6817
2010's3 (75.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Balassiano, IT; Boente, RF; Brazier, J; Domingues, RM; dos Santos-Filho, J; Hall, V; Lobo, LA; Miranda, KR; Nouér, SA; Secco, DA1
Hangaishi, A; Kurokawa, M; Masamoto, Y; Nannya, Y; Shinohara, A; Yoshiki, Y1
Haeusler, GM; Slavin, MA1
Friedrich, A; Martino, P; Micozzi, A; Monaco, M; Tarasi, A; Venditti, M1

Other Studies

4 other study(ies) available for moxifloxacin and Hematologic Neoplasms

ArticleYear
Clostridium difficile infection among immunocompromised patients in Rio de Janeiro, Brazil and detection of moxifloxacin resistance in a ribotype 014 strain.
    Anaerobe, 2014, Volume: 28

    Topics: Adult; Anti-Bacterial Agents; Bacterial Toxins; Brazil; Clostridioides difficile; Clostridium Infections; Cross Infection; Drug Resistance, Bacterial; Enzyme-Linked Immunosorbent Assay; Feces; Female; Fluoroquinolones; Hematologic Neoplasms; Humans; Immunocompromised Host; Male; Moxifloxacin; Ribotyping

2014
Moxifloxacin is more effective than tosufloxacin in reducing chemotherapy-induced febrile neutropenia in patients with hematological malignancies.
    Leukemia & lymphoma, 2013, Volume: 54, Issue:4

    Topics: Adult; Aged; Antibiotic Prophylaxis; Antineoplastic Agents; Aza Compounds; Female; Fever; Fluoroquinolones; Hematologic Neoplasms; Humans; Male; Middle Aged; Moxifloxacin; Naphthyridines; Neutropenia; Quinolines; Retrospective Studies; Risk Factors; Treatment Outcome

2013
Fluoroquinolone prophylaxis: worth the cost?
    Leukemia & lymphoma, 2013, Volume: 54, Issue:4

    Topics: Antineoplastic Agents; Aza Compounds; Female; Fever; Fluoroquinolones; Hematologic Neoplasms; Humans; Male; Moxifloxacin; Naphthyridines; Neutropenia; Quinolines

2013
In vitro activity of moxifloxacin against Stenotrophomonas maltophilia blood isolates from patients with hematologic malignancies.
    Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases, 2001, Volume: 7, Issue:1

    Topics: Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Bacteremia; Blood; Fluoroquinolones; Gram-Negative Bacterial Infections; Hematologic Neoplasms; Humans; Microbial Sensitivity Tests; Moxifloxacin; Quinolines; Stenotrophomonas maltophilia

2001